Stomach Cancer Statistics (Cont.)

Stomach Cancer Statistics: Survival Rates

Survival rates can be calculated by different methods for different purposes. The stomach cancer survival rates presented here are based on the relative survival rate, which measures the survival of the stomach cancer patients in comparison to the general population. The overall five-year relative stomach cancer survival rate for 1995-2001 was 23.2 percent.
 
Five-year relative survival rates for stomach cancer by race and sex were:
 
  • 19.9 percent for white men
  • 23.9 percent for white women
  • 21.5 percent for black men
  • 24.2 percent for black women.
 

Stomach Cancer Statistics: Stage Impact

The stomach cancer stage plays a role in the prognosis for people with the disease. Based on historical data:
 
  • 24 percent of stomach cancer cases are diagnosed while the cancer is still confined to the primary site (localized stage)
 
  • 32 percent are diagnosed after the cancer has spread to regional lymph nodes or directly beyond the primary site (regional stage)
 
  • 32 percent are diagnosed after the cancer has already metastasized (distant stage)
 
  • 12 percent of cases had staging information that was unknown.
 
The corresponding five-year relative stomach cancer survival rates were:
 
  • 58.0 percent for localized
  • 21.9 percent for regional
  • 3.1 percent for distant
  • 12.4 percent for unstaged.
 

Stomach Cancer Statistics: Lifetime Risk

Based on rates from 2000-2002, 1 in 103 men and women will be diagnosed with stomach cancer during their lifetime. These statistics are referred to as the lifetime risk of developing stomach cancer. Sometimes it is more useful to look at the probability of developing stomach cancer between two age groups. For example, 0.43 percent of men will develop stomach cancer between their 50th and 70th birthdays, compared to 0.21 percent of women.
 
(Stomach Cancer Statistics Continued: Page 3)
Pages:

Previous 1   2   3 Next

Written by/reviewed by: Arthur Schoenstadt, MD
Last reviewed by: Arthur Schoenstadt, MD